Elite Pharmaceuticals Inc (ELTP)

[gordonhoochie]

Abuse Resistant and Sustained Release Opioids

A once-daily oxycodone formulation was developed by Elite, using its proprietary technology. An investigational new drug application, or IND, has been filed and Elite has completed two pharmacokinetic studies in healthy subjects that compared blood levels of oxycodone from dosing the once-daily product and the twice-a-day product, OxyContin® marketed in the U.S. by Purdue Pharma LP. These studies confirmed that the Company’s once-daily product, when compared to twice-daily delivery, demonstrated an equivalent onset, more constant blood levels of the drug over the 24 hour period and equivalent blood levels to the twice-a-day product at the end of 24 hours. Elite has successfully manufactured multiple batches on commercial scale equipment



Pretty surprised no one has made comments on this yet. Studies done on live patients and they basically compared 216 to Purdues current product. Studies showed that 216 was better then Purdues.